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Abstract
Purpose To evaluate overall survival for atypical teratoid rhabdoid tumors (ATRTs) in relation to extent of surgical resection.
Methods The neurosurgical tumor databases from three UK Pediatric centers (University Hospital of Wales, Alder Hey and
Royal Manchester Children’s Hospital) were analyzed. Patients with a diagnosis of ATRT were identified between 2000 and
2018. Data was collected regarding demographics, extent of resection, complications, and overall survival.
Results Twenty-four patients diagnosed with ATRT underwent thirty-eight operations. The age range was 20 days to
147 months (median 17.5 months). The most common location for the tumor was the posterior fossa (nine patients;
38%). Six patients (25%) underwent a complete total resection (CTR), seven (29%) underwent a near total resection
(NTR), eight (33.3%) underwent a subtotal resection (STR), and three patients (12.5%) had biopsy only. Two-thirds of
patients who underwent a CTR are still alive, as of March 2019, compared to 29% in the NTR and 12.5% in the STR
groups. Out of the thirty-eight operations, there were a total of twenty-two complications, of which the most common
was pseudomeningocele (27%). The extent of surgical resection (p = 0.021), age at surgery (p = 0.00015), and the
presence of metastases at diagnosis (0.015) significantly affected overall survival.
Conclusions Although these patients are a highly vulnerable group, maximal resection is recommended where possible, for the
best chance of long-term survival. However, near total resections are likely beneficial when compared with subtotal resections
and biopsy alone. Maximal surgical resection should be combined with adjuvant therapies for the best long-term outcomes.
Keywords Neuro-oncology . Central nervous system . Brain tumor . Neurosurgery
Introduction
Atypical teratoid rhabdoid tumors (ATRTs) are rare, embryo-
nal malignancies found predominantly in infancy. They rep-
resent 1–2% of childhood central nervous system (CNS)
tumors, with a peak incidence in children less than 3 years
of age (10–15%) [24]. They are characterized by bi-allelic loss
of function mutations in typically SMARCB1, or rarely
SMARCA4, encoding for sub-units of the SWI/SNF chromatin
remodeling complex [13, 19, 31]. Previously, ATRTs were
labeled as primitive neuroectodermal tumor, choroid plexus
tumor, or medulloblastoma, until their distinct morphology
was identified in 1978 [3]. These tumors were finally given
their own formal classification by the World Health
Organization in 2000, which now requires molecular confir-
mation of the characteristic mutations [16, 23, 24, 27]. Despite
developments in cancer research, the prognosis of ATRTs re-
mains poor, with a median survival reported between 6 and
12 months [7–9, 12, 27, 29]. ATRTs are mostly managed with
a combination of surgery followed by adjuvant oncological
treatment. However, there is still significant ambiguity in the
literature regarding optimal treatment. The aim of this study is
to evaluate the efficacy of surgical resection in relation to
survival for children with ATRTs.
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Materials and methods
A retrospective analysis of three prospectively collected UK
pediatric neurosurgical databases was performed (University
Hospital of Wales, Alder Hey Hospital and The Royal
Manchester Children’s Hospital). Patients with a confirmed
histological diagnosis of ATRT were identified since January
2000. Case notes of these patients were reviewed along with
all their radiology, and a database was compiled to collate data
such as location of tumor, extent of surgical resection, surviv-
al, and postoperative complications.
Patients were grouped according to extent of surgical
resection of their tumor. Cases that underwent more than
one operation were categorized with their best extent of
surgical resection. Complete total resection (CTR) is de-
fined as no residual tumor seen on postoperative imaging
[21]. Near total resection (NTR) is described as more than
90% tumor removal and subtotal resection (STR) is within
the range of 10% to 90% of tumor resected. “Biopsy” was
defined as any operation with less than 10% tumor resec-
tion. All grades of resection were quantitatively confirmed
with postsurgical magnetic resonance imaging and volu-
metric studies with the neuroradiologists.
Statistical analysis
Statistical analyses were computed using IBM SPSS
Statistics (Version 25; 2019). Survival analysis was per-
formed by the Kaplan-Meier method with significance
values for comparisons established by the log rank test.
Overall survival (OS) was defined in years from the date
of tumor diagnosis to the date of death or censorship if
alive. A p value of less than 0.05 was considered statisti-
cally significant. Multivariate analysis was carried out
using cox regression.
Results
Twenty-four patients diagnosed with ATRTs underwent thirty-
eight operations in total. The age range was from 20 days to
147 months (median: 17.5 months). Twelve (50%) were fe-
male and twelve (50%) were male. Seventeen patients had one
operation, four patients had two, and one patient each had
three, four, and six operations, respectively. The most com-
mon location for the tumor was the posterior fossa, which
included nine patients (38%). Of these, one-third had exten-
sion into the fourth ventricle (Fig. 1). Five patients (21%) had
metastases at initial presentation.
In our study, six patients (25%) underwent a CTR, and
seven (29%) underwent an NTR. Eight patients (33.3%) had
STR, and three patients (12.5%) had biopsy only (Fig. 2).
Complete total resection group
Four patients (66.6%) had initial CTR and are still alive as of
March 2019 (7 to 158 months from surgery; group median
19.5 months). Two out of six (33.3%) are now deceased.
Near total resection group
Of the seven patients who underwent NTR, two patients
(29%) remain alive (85 and 127 months from surgery; group
median 6 months) and five (71%) are deceased.
Subtotal resection group
In the STR group, one patient (12.5%) is alive (44 months
from surgery) and seven (87.5%) are deceased.
Biopsy only group
In the biopsy group, one patient remains alive (33.3%)












































Fig. 2 Overall survival in patients undertaking surgical procedures
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deceased. The median survival for the STR and BO groups
combined is 6 months.
Survival analysis
Univariate analysis was carried out to ascertain variables
which may influence survival in the study cohort. Overall
survival within the CTR group was significantly higher com-
pared to the NTR and STR groups (p = 0.048, Fig. 3).
Concordantly, survival was significantly worse in STR groups
when compared to all patients who underwent near or com-
plete total resections (p = 0.021; Fig. 4). Survival was also
significantly worse in patients presenting under the age of
one (p = 0.00015) and those who had metastases at initial di-
agnosis (p = 0.015; Figs. 5 and 6).
Multivariate analysis using the cox regression method was
conducted. Older age was still significantly associated with
longer survival (p = 0.008). While extent of resection still
showed a trend toward significance, (p = 0.125) the presence
of metastases was not significantly associated with an effect
on survival in this analysis (p = 0.316).
Neurosurgical complications
Within the thirty-eight studied operations, there were twenty-
two complications (Table 1). The most common complication
was pseudomeningocele (six patients; 25%). Eight out of the
twenty-four patients (33.3%) required a ventriculoperitoneal
shunt for hydrocephalus.
Twenty-two patients (96%) received adjuvant chemothera-
py (CMT) as per the European Rhabdoid Tumor Registry
(EU-RHAB) 2007 Protocol. Eleven patients (46%) underwent
radiotherapy (RT) postoperatively. Twelve patients received
triple modality therapy (surgery, chemotherapy and radiother-
apy) – of which 50% have survived (Fig. 7).
Discussion
ATRT is a highly malignant neoplasm associated with a poor
prognosis. It is primarily found in infancy; however, it has
been diagnosed both antenatally and in adults [1, 10, 17].
Due to the lack of large prospective studies regarding ATRT,
there is still uncertainty regarding the optimal treatment for
these children and therefore, management strategies vary. It
is, however, generally accepted that these patients need a com-
bination of surgical resection followed by adjuvant chemo-
therapy (as per the European Rhabdoid Tumor Registry
2007 Protocol) plus or minus radiotherapy, according to age
at presentation [7, 8, 27].
The majority of studies have been unable to quantify
the significance of extent of surgical resection with regard
to long-term survival. However, others have inferred that
surgery appears to influence prognosis. Hilden et al. re-
ported increased event-free survival of 14 months in pa-
tients who underwent a CTR compared to 9.25 months for
those who had a STR [17]. Athale et al. identified an
overall survival of 21.3 months for a CTR in contrast to
12.3 months for a STR and 10.2 months for biopsy alone
[2]. However, these authors also state that, with a postop-
erative mortality rate of 4%, surgery may not be beneficial
above receiving chemotherapy alone. Conversely, more
recent work by Biswas et al. and Lafay-Cousin et al. sug-
gest that CTR correlates with an increased 2-year survival
from 21.7% (STR) to 60% (CTR) [7, 22]. This is similar
to the findings of the present study, which identified a
trend toward increased survival with maximal resection
(66.6% compared to 29% and 12.5% in the NTR and
STR groups, respectively; Table 1).
This study identified that extent of resection, older age,
and the presence of metastases, at presentation, were sig-
nificantly associated with overall survival in univariate
analysis. This corroborates the results of other case series

















Fig. 3 Kaplan-Meier curves
comparing survival of patients
after CTR, NTR, and STR. Log-
rank test identified that greater
resection was significantly asso-
ciated with increased survival
(p = 0.048)
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resection with increased survival [7, 15, 17, 18, 22, 29].
Previous studies have estimated that 30% of patients will
have metastatic disease at presentation, of which there is a
higher incidence in patients less than 3 years old [12, 29].
Dufour et al. identified that patients younger than 2 years
old had a poorer 1 year overall survival in univariate
analysis (34% compared to 55% in the younger and older
groups, respectively) [12]. Likewise, Tekautz et al. report-
ed superior 2-year overall survival in patients older than
3 years old (89% ± 17%) compared to the younger cohort
(17% ± 9%) [30].This is possibly due to an increased
chance of CTR, ability to undergo radiotherapy plus a
lower chance of metastases at presentation.
In subsequent multivariate analysis, younger age
remained a significant factor for mortality, while extent
of resection demonstrated a trend toward significance.
Metastases at presentation were not associated with a sur-
vival effect in multivariate testing. This may be attributed
to the present study being underpowered to fully detect
the impact of resection and metastases upon survival dur-
ing a multivariate analysis, and thus a larger cohort anal-
ysis may subsequently confirm the extent to which
resection type impacts upon survival. It may also be pos-
sible that the effect of younger age at surgery is of such a
magnitude that it contributes to the impact of surgical
resection and metastases during univariate analyses.
While many studies highlight the significance of maximal
resection in terms of survival, several report that extent of
resection is not significant when matched with other prog-
nostic indicators [2, 9, 12, 17]. These incongruities are
likely due to the lack of large, prospective studies needed
to evaluate prognosis and warrants further exploration.
Some studies have suggested the importance of subse-
quent surgeries to obtain maximal resection, agreeing
with the verdict that CTR is a positive prognostic indict-
or. Von Hoff et al. noted that four out of eighteen
(22.2%) patients in their case series underwent a second
surgery to achieve complete resection of their ATRT and
thus recommend additional procedures, where possible,
for increased event-free survival [32]. Furthermore,
Fidani et al. reported that surgical resection may be ben-
eficial even in relapsed patients, emphasizing the impor-
tance of re-do surgical interventions [14]. In our cohort,
seven patients (29%) required more than one surgical
Fig. 5 Kaplan-Meier curves
comparing survival of patients
when operated at age < 1 yr or >
1 yr. Log-rank test identified that
the older age group was
significantly associated with


















Fig. 4 Kaplan-Meier curves
comparing survival of patients
after STR or Biopsy verses all
other more extensive surgeries,
(NTR or CTR together). Log-rank
test identified that subtotal
resection was significantly
associated with reduced survival
(p = 0.021)
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procedure. Two patients within this sub-cohort had con-
firmed CTR. Despite this, both of these patients are de-
ceased. Re-do surgery is challenging and remains of un-
certain benefit; therefore, its use should be considered on
a case-by-case basis.
Although CTR is favorable for survival, it is not al-
ways feasible to achieve this. Only 25% of patients in
our study underwent a CTR. There did not appear to be
a correlation between the location of the tumor and extent
of surgical resection in this study. Postoperative radiother-
apy was offered to 83% of patients in the CTR group
compared to 39% in the non-CTR group. This difference
could be due to the fact that the non-CTR group consists
of a younger cohort, to whom treating clinicians may be
reticent to give radiotherapy.
Chi et al. concurs that CTR is favorable, with a 2-year
overall survival of 91%, although, their report concluded
that an aggressive, multimodal regimen is the optimum
for long-term survival [11]. Upon reviewing data from
the National Cancer Institute, Buscariollo et al. informed
that they did not observe any consistency with the extent
of surgery in relation to overall survival outcomes so have
implicated that surgical resection alone is not adequate
[9]. This is further elucidated by Rorke et al. who reported
that nine children died postoperatively after not receiving
any adjuvant therapy, providing further evidence for the
need for chemotherapy plus or minus radiotherapy after
surgical resection [28]. Additionally, Ren et al. found im-
proved 2-year survival outcomes of 57.1% using a com-
bination of therapies (including gamma-knife surgery) in
comparison to 18.9% with other therapies alone [26]. In
our report, twelve patients received adjuvant chemothera-
py and radiotherapy, of which 50% have survived. This is
the highest overall survival in all of our treatment groups
(Fig. 7), which supports the findings of several other re-
ports within the literature [8, 11, 14, 15, 18, 25, 27].
Germline mutations of SMARCB1/SMARCA4 have also
been associated with poorer survival [10, 13, 27, 28],
while newer evidence purports an association with molec-
ular subgrouping [17, 31]. Germline mutations of
SMARCB1 appear to predispose patients to synchronous
rhabdoid tumors within and out-with the CNS [3, 4].
Numerous reports have observed that these patients have
a worse prognosis [3–6, 10, 16, 20]. Therefore, identifi-
cation of genetic profiles and phenotypes of ATRTs re-


















Fig. 6 Kaplan-Meier curves
comparing survival of patients
who had metastases at diagnosis
with those who did not have
evidence of metastatic disease.
Log-rank test identified that the
absence of metastases at
diagnosis was significantly




























Fig. 7 Outcomes for patients receiving different combinations of therapy
for ATRTs
Table 1 Neurosurgical complications
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Conclusion
This is a highly vulnerable group of patients undergoing com-
plex neurosurgical procedures with high risk of surgical mor-
bidity. Although ATRTs have a poor prognosis, we recom-
mend maximal resection for the best chance of long-term sur-
vival. However, near total resection is likely beneficial when
compared with subtotal resection and biopsy alone. Maximal
surgical resection should be combined with adjuvant therapies
for the best long-term outcomes.
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